BEATHealthcare · Health Information ServicesThe 4 Wall Street analysts covering HeartBeam, Inc. hold a median 12-month price target of $3.25 — +536.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 6 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores HeartBeam, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own HeartBeam, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on BEAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +536.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 July 2026 | Maxim Group | Initiates | Buy | $2.00 |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | $5.50 → $2.50 |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | Benchmark | Maintains | Speculative Buy | $8.00 → $5.00 |
| 15 May 2026 | Benchmark | Maintains | Speculative Buy | — |
| 31 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 30 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | D. Boral Capital | Initiates | Buy | — |
| 16 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2025 | Benchmark | Upgrade | Buy | — |
| 10 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 Nov 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 4 Sept 2024 | Benchmark | Reiterates | Speculative Buy | $8.00 |
| 13 May 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 25 Mar 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 16 Nov 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 24 Aug 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 19 May 2023 | Alliance Global Partners | Maintains | Buy | — |
| 19 May 2023 | Benchmark | Reiterates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 3% of US stocks
Cheaper than 68% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAT appears on the weeks it earns a place.
HeartBeam, Inc. announced it will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. Eastern Time to discuss its second quarter 2026 financial results.
Why it matters — The call will provide investors with the company's latest financial performance and business updates for the second quarter of 2026.
The 4 Wall Street analysts covering HeartBeam, Inc. have a median 12-month price target of $3.25, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering HeartBeam, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartBeam, Inc. 36 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Aug 2026, HeartBeam, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +536.8% from the last close, and Ticker Nerd's factor model ranks HeartBeam, Inc. 36 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HeartBeam, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
HeartBeam, Inc. returned -46.3% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
HeartBeam Inc. is a medical technology company focused on transforming cardiac disease detection and monitoring through innovative electrocardiogram solutions.
The most recent item we track (Business Wire, 30 July 2026): "HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time". HeartBeam, Inc. announced it will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. Eastern Time to discuss its second quarter 2026 financial results.
HeartBeam Inc. is a medical technology company focused on transforming cardiac disease detection and monitoring through innovative electrocardiogram solutions. The company has developed the first cable-free device capable of collecting electrocardiogram signals in three dimensions from non-coplanar directions and synthesizing them into clinical-grade 12-lead electrocardiograms. HeartBeam's flagship product, HeartBeam AIMIGo, is a credit card-sized portable device coupled with a smartphone application and cloud-based diagnostic software system that enables remote evaluation of cardiac symptoms outside traditional healthcare settings. The company's proprietary Vector Electrocardiography platform creates three-dimensional vector images of cardiac electrical activity, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. HeartBeam received FDA clearance for its 3D electrocardiogram technology for arrhythmia assessment in December 2024 and for its 12-lead electrocardiogram synthesis software in December 2025. The platform is designed for use in both clinical and at-home settings, with readings reviewed by on-demand board-certified cardiologists. Founded in 2015 and headquartered in Santa Clara, California, HeartBeam holds over 20 issued patents related to its technology and is advancing applications in heart attack detection and artificial intelligence-enabled cardiac screening.
CEO Mr. Robert P. Eno · 17 employees · United States · https://www.heartbeam.com